US equities |
SPCX $167.09 ▲+5.11% NVDA $236.40 ▲+1.05% MU $1,063.71 ▼-1.04% TSLA $378.43 ▲+2.12% MSFT $525.12 ▲+1.47% SNDK $1,707.61 ▼-0.72% INTC $117.33 ▼-1.68% META $743.41 ▲+2.11%
FinancialContent

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

15.26 +0.06 (+0.39%)
Delayed Quote Updated: 12:23 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Participate in Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗
Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare? 
Via The Motley Fool
News headline image
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare. 
Via The Motley Fool
News headline image
Dyne Therapeutics Appoints Barry Greene to Board of Directors
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
Via The Motley Fool
News headline image
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics to Participate in Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >